ArticleAmerican journal of human genetics1994
A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1.
Article in American journal of human genetics, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 80 citations in OpenAlex.
- Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.Molecular cancer therapeutics · 2009Trial
- Detecting TP53 mutations in paired liquid and tissue biopsies from patients with high-grade serous ovarian carcinoma.International journal of cancer · 2026Article
- Integrating network pharmacology and Mendelian randomization to explore potential targets of matrine against ovarian cancer.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024Article
- Differential requirement for BRCA1-BARD1 E3 ubiquitin ligase activity in DNA damage repair and meiosis in the Caenorhabditis elegans germ line.PLoS genetics · 2023Article
- In Vitro Reconstitution of BRCA1-BARD1/RAD51-Mediated Homologous DNA Pairing.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Accelerated aging in normal breast tissue of women with breast cancer.Breast cancer research : BCR · 2021Article
- BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis.Frontiers in cell and developmental biology · 2021Review
- Novel role of BRCA1 interacting C-terminal helicase 1 (BRIP1) in breast tumour cell invasion.Journal of cellular and molecular medicine · 2020Article
- Article
- TP53 Mutations in Breast and Ovarian Cancer.Cold Spring Harbor perspectives in medicine · 2017Review
- Identifying breast cancer risk loci by global differential allele-specific expression (DASE) analysis in mammary epithelial transcriptome.BMC genomics · 2012Article
- Identifying putative breast cancer-associated long intergenic non-coding RNA loci by high density SNP array analysis.Frontiers in genetics · 2012Article
- Article
- Mutations in BRIP1 confer high risk of ovarian cancer.Nature genetics · 2011Article
- Expression of FK506 binding protein 65 (FKBP65) is decreased in epithelial ovarian cancer cells compared to benign tumor cells and to ovarian epithelium.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2011Article
- Genomic aberrations in borderline ovarian tumors.Journal of translational medicine · 2010Article
- Tumor spreading to the contralateral ovary in bilateral ovarian carcinoma is a late event in clonal evolution.Journal of oncology · 2010Article
- BACH1 Ser919Pro variant and breast cancer risk.BMC cancer · 2006Article
- Article
- Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder.British journal of cancer · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Linkage analysis in familial breast and ovarian cancer and studies of allelic deletion in sporadic ovarian tumors have identified a region on chromosome 17q containing a candidate tumor-suppressor gene (referred to as BRCA1) of likely importance in ovarian carcinogenesis. We have examined normal and tumor DNA samples from 32 patients with sporadic and 8 patients with familial forms of the disease, for loss of heterozygosity (LOH) at 21 loci on chromosome 17 (7 on 17p and 14 on 17q). LOH on 17p was 55% (22/40) for informative 17p13.1 and 17p13.3 markers. When six polymorphic markers flanking the familial breast/ovarian cancer susceptibility locus on 17q12-q21 were used, LOH was 58% (23/40), with one tumor showing telomeric retention. Evaluation of a set of markers positioned telomeric to BRCA1 resulted in the highest degree of LOH, 73% (29/40), indicating that a candidate locus involved in ovarian cancer may reside distal to BRCA1. Five of the tumors demonstrating allelic loss for 17q markers were from individuals with a strong family history of breast and ovarian cancer. More important, two of these tumors (unique patient number [UPN] 57 and UPN 79) retained heterozygosity for all informative markers spanning the BRCA1 locus but showed LOH at loci distal to but not including the anonymous markers CMM86 (D17S74) and 42D6 (D17S588), respectively. Deletion mapping of seven cases (two familial and five sporadic) showing limited LOH on 17q revealed a common region of deletion, distal to GH and proximal to D17S4, that spans approximately 25 cM. These results suggest that a potential tumor-suppressor gene involved in both sporadic and familial ovarian cancer may reside on the distal portion of chromosome 17q and is distinct from the BRCA1 gene.
Indexed as
Identifiers
7942844PMC1918278W1498750456What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.